Trade Gyre Therapeutics Inc - GYRE CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.1116 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.01 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 15.8392 |
| Open | 15.7992 |
| 1-Year Change | 6617.35% |
| Day's Range | 15.5492 - 16.1592 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 23, 2024 | 15.8392 | 0.0400 | 0.25% | 15.7992 | 16.0792 | 15.4992 |
| Apr 22, 2024 | 15.7992 | 0.3000 | 1.94% | 15.4992 | 16.3992 | 15.0992 |
| Apr 19, 2024 | 15.4992 | 0.5900 | 3.96% | 14.9092 | 15.7392 | 14.5592 |
| Apr 18, 2024 | 15.2492 | -0.2500 | -1.61% | 15.4992 | 15.9392 | 15.0692 |
| Apr 17, 2024 | 15.7592 | -0.0200 | -0.13% | 15.7792 | 16.3592 | 15.2992 |
| Apr 16, 2024 | 15.9392 | -0.0600 | -0.38% | 15.9992 | 16.0092 | 15.6792 |
| Apr 15, 2024 | 16.4292 | 0.2800 | 1.73% | 16.1492 | 16.4292 | 15.9992 |
| Apr 12, 2024 | 16.7592 | 0.9800 | 6.21% | 15.7792 | 16.9492 | 15.7792 |
| Apr 11, 2024 | 16.2992 | 1.7900 | 12.34% | 14.5092 | 16.6292 | 14.5092 |
| Apr 10, 2024 | 13.6292 | -3.0700 | -18.38% | 16.6992 | 16.8692 | 13.2792 |
| Apr 9, 2024 | 16.9692 | 0.1100 | 0.65% | 16.8592 | 16.9892 | 16.4992 |
| Apr 8, 2024 | 16.7392 | 0.0900 | 0.54% | 16.6492 | 17.0092 | 16.6492 |
| Apr 5, 2024 | 16.7292 | 0.0300 | 0.18% | 16.6992 | 17.0092 | 16.4992 |
| Apr 4, 2024 | 16.7492 | 0.2000 | 1.21% | 16.5492 | 17.2992 | 16.2192 |
| Apr 3, 2024 | 16.8992 | 0.6200 | 3.81% | 16.2792 | 17.1392 | 16.1992 |
| Apr 2, 2024 | 16.8192 | 1.0900 | 6.93% | 15.7292 | 16.9492 | 15.5792 |
| Apr 1, 2024 | 15.8492 | -1.2500 | -7.31% | 17.0992 | 17.0992 | 15.7992 |
| Mar 28, 2024 | 17.1892 | 0.1900 | 1.12% | 16.9992 | 18.1992 | 16.9992 |
| Mar 27, 2024 | 17.3292 | 0.8800 | 5.35% | 16.4492 | 17.8692 | 16.3392 |
| Mar 26, 2024 | 16.4792 | 0.0800 | 0.49% | 16.3992 | 17.6292 | 16.3992 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Catalyst Biosciences, Inc. Company profile
About Catalyst Biosciences Inc
Catalyst Biosciences, Inc., formerly Targacept, Inc. is a research and clinical development biopharmaceutical company. The Company is focused on medical needs in disorders of the complement and coagulation systems. Its protease engineering platform has generated two late-stage clinical programs, including marzeptacog alfa (MarzAA), a subcutaneously (SQ) administered engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders in patients with Hemophilia A or B with inhibitors. Its clinical trial of MarzAA in Factor VII Deficiency, Glanzmann Thrombasthenia, and Hemophilia A with inhibitor patients on prophylaxis Hemlibra for treatment of episodic bleeding (MAA-202). The Company pipeline also includes dalcinonacog alfa (DalcA), a subcutaneously (SQ) Factor IX (FIX) to prevent bleeding episodes for Hemophilia B patients. Its discovery stage Factor IX gene therapy construct, CB 2679d-GT for Hemophilia B.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Catalyst Biosciences Inc revenues decreased 74% to $4.9M. Net loss increased 81% to $67.6M. Revenues reflect License decrease from $15.1M to $0K. Higher net loss reflects Research and development increase of 3% to $38.3M (expense), General and administrative - Balancing v increase of 9% to $11.3M (expense), Miscellaneous income (expense) decrease of 99% to $8K (income).
Equity composition
Common Stock $.001 Par, 04/11, 100M auth., 29,021,460 issd., Insiders control approx. 0.08%. IPO: 4/06 5,000,000 shs. @ $9per share by Deutsche Bank Securities. 8/15, 1-for-7 reverse stock split.
| Industry: | Biotechnology & Medical Research (NEC) |
12770 High Bluff Drive, Suite 150
SAN DIEGO
CALIFORNIA 92130
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com